1. Search Result
Search Result
Results for "

C57BL/6B mice

" in MedChemExpress (MCE) Product Catalog:

1890

Inhibitors & Agonists

15

Fluorescent Dye

20

Biochemical Assay Reagents

154

Peptides

45

Inhibitory Antibodies

309

Natural
Products

19

Recombinant Proteins

42

Isotope-Labeled Compounds

10

Antibodies

10

Click Chemistry

45

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0939

    Chicago Sky Blue 6B

    Amyloid-β NF-κB Inflammation/Immunology
    Direct Blue 1 (Chicago Sky Blue 6B) is a complex dye for background autofluorescence in immunofluorescence histochemistry. Direct Blue 1 is a potent and competitive VGLUT inhibitor. Direct Blue 1 can inhibit the Aβ-binding small molecule PrP ligand. Direct Blue 1 has anti-inflammatory activity [6].
    Direct Blue 1
  • HY-117427

    Others Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-122615B
    SPOP-IN-6b dihydrochloride
    1 Publications Verification

    Others Cancer
    SPOP-IN-6b dihydrochloride is a potent speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM .
    SPOP-IN-6b dihydrochloride
  • HY-122615
    SPOP-IN-6b
    1 Publications Verification

    Others Cancer
    SPOP-IN-6b is a speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM (patent CN 107141287, SPOP-B-88) .
    SPOP-IN-6b
  • HY-W110925

    Biochemical Assay Reagents Others
    Alkali blue 6B monosodium (IND) is a basic dye that can be used as a reagent in biochemical and medical research. Alkali blue 6B monosodium (IND) interacts with various proteins, and can be used in protein adsorption studies. Alkali blue 6B monosodium (IND) contains SO3H -, NH and OH groups that may react with divalent heavy metal ions, and can be used for the removal of heavy metals from aqua .
    Alkali blue 6B monosodium(IND)
  • HY-160025

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO antagonist-1 (compound 163) is an antagonist of IDO . IDO antagonist-1 inhibits pancreatic adenocarcinoma cells growth in C57BL/6 mice .
    IDO antagonist-1
  • HY-128435

    Others Metabolic Disease
    2,4'-Dihydroxybenzophenone ((Z)-SU4312) exhibited estrogenic activities. 2,4'-Dihydroxybenzophenone has oral bioactivity that can effectively protect C57BL/6J mice from Acetaminophen (HY-66005, APAP)-induced hepatotoxicity .
    2,4'-Dihydroxybenzophenone-1
  • HY-157429

    5-HT Receptor Neurological Disease
    25N-N1-Nap (compound 16) is a β-arrestin-biased 5-HT2A agonist. 25N-N1-Nap antagonizes phencyclidine induced hyperactivity in Male C57BL/6 J mice .
    25N-N1-Nap
  • HY-144743

    Phosphodiesterase (PDE) Others
    ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC50 of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .
    ATX inhibitor 12
  • HY-122615A

    Others Cancer
    SPOP-IN-6b hydrochloride is a potent speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM .
    SPOP-IN-6b hydrochloride
  • HY-168081

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-52 (Compound III-5) is an orally active PD-1/PD-L1 inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC50 of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .
    PD-1/PD-L1-IN-52
  • HY-147663

    Carbonic Anhydrase Cancer
    Compounds 6b and 14g showed significant inhibitory effect on tumor related subtype HCA IX with low nanomolar potency, while 6k was effective on HCA XII. Compounds 6b, 14g and 6k can be considered as the leading molecules for the development of future cancer therapeutic drugs based on new mechanisms of action.
    hCAIX-IN-6
  • HY-145897

    iGluR Neurological Disease
    NMDA-IN-2 (compound 6b), a Procaine derivative, is a NMDA receptor 2B subtype inhibitor .
    NMDA-IN-2
  • HY-14690B

    rel-SCH 39166 hydrobromide

    Dopamine Receptor Neurological Disease
    rel-Ecopipam (rel-SCH 39166) (Compound 6b) hydrobromide is a D1 receptor antagonist (Ki: 1.30 nM) .
    rel-Ecopipam hydrobromide
  • HY-126117

    Fungal Carbonic Anhydrase Infection
    (+)-Xylariamide A (compound 6b) is a mycobacterial and fungal carbonic anhydrase probe with inhibitory activity against pathogen β-carbonic anhydrases .
    (+)-Xylariamide A
  • HY-155057

    SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-8 (compound 6b) is an antiviral agent with anti-SARS-CoV-2 properties .
    SARS-CoV-2 Mpro-IN-8
  • HY-162909

    Tyrosinase Metabolic Disease
    Tyrosinase-IN-38 (compound 6b) is a competitive Tyrosinase inhibitor with IC50 value of 25.82 μM. Tyrosinase-IN-38 has antioxidant activity .
    Tyrosinase-IN-38
  • HY-W171983

    Others Cancer
    Notum-IN-1 (compound 6b) is an orally active, selective and brain penetrant inhibitor of Notum. Notum-IN-1 blocks the Wnt signaling in vivo in mouse .
    Notum-IN-1
  • HY-156414

    Dihydrofolate reductase (DHFR) Infection
    DHFR-IN-11 (compound 6b) is inhibitor of DHFR, and has inhibitory potency versus M. tuberculosis DHFR enzyme with IC50 values 5.70 μM .
    DHFR-IN-11
  • HY-147662

    Carbonic Anhydrase Cancer
    hCAIX-IN-5 (compound 6b) is a potent and selective hCAIX inhibitor with KIs of >10000, >10000, 130.7, 829.1 nM for hCAI, hCAII, hCAIV, hCAIX, respectively .
    hCAIX-IN-5
  • HY-163397

    Fungal Infection
    Antibacterial agent 196 (compound 6b) is a coumarin derivative containing oxime ether structure, and shows antifungal activity, with the EC50 of 0.46 μg/mL against Rhizoctonia solani .
    Antibacterial agent 196
  • HY-144383

    RAR/RXR Others
    RXR antagonist 2 (compound 6b) is a potent antagonist of RXR with a Ki and Kd of 0.391 and 0.281 μM. RXR antagonist 2 has the potential for the research of RXR related diseases .
    RXR antagonist 2
  • HY-123707

    Microtubule/Tubulin Cancer
    KPU-300 (compound 6b) is a tubulin inhibitor. KPU-300 has potent cytotoxicity with an IC50 value of 7.0 nM against HT-29 cells .
    KPU-300
  • HY-161475

    Others Others
    Luciferase-IN-4 (Compound 6b) is an inhibitor for luciferase with IC50 of 4.1 μM. Luciferase-IN-4 inhibits purified luciferase in P. pyralis with IC50 of 2.0 μM .
    Luciferase-IN-4
  • HY-130716

    E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis Cancer
    Thalidomide-NH-C10-COOH (compound 6b) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and a linker used in PROTAC technology .
    Thalidomide-NH-C10-COOH
  • HY-102090

    CD28 Inflammation/Immunology
    B7/CD28 interaction inhibitor 1 (copmound 6b) is a potent B7.1-CD28 interaction inhibitor with an IC50 of 50 nM .
    B7/CD28 interaction inhibitor 1
  • HY-N10906

    Others Others
    (4R,4aS,5aS,6aR,6bS,7aR)-4-Hydroxy-3,6b-dimethyl-5-methylene-4,4a,5,5a,6,6a,7,7a-octahydrocyclopropa[2,3]indeno[5,6-b]furan-2(6bH)-one is a sesquiterpene lactone .
    (4R,4aS,5aS,6aR,6bS,7aR)-4-Hydroxy-3,6b-dimethyl-5-methylene-4,4a,5,5a,6,6a,7,7a-octahydrocyclopropa[2,3]indeno[5,6-b]furan-2(6bH)-one
  • HY-151143

    Glucosidase Metabolic Disease
    α-Glucosidase-IN-19 (Compound 6B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 3.63 μM. α-Glucosidase-IN-19 shows anti-diabetic activity .
    α-Glucosidase-IN-19
  • HY-158262

    Bradykinin Receptor Neurological Disease
    Bradykinin B1 receptor antagonist 1 (compound 6B) is a potent and cross the blood-brain barrier bradykinin B1 antagonist. Bradykinin B1 receptor antagonist 1 has the potential for the research of pain .
    Bradykinin B1 receptor antagonist 1
  • HY-169010

    E3 Ligase Ligand-Linker Conjugates Infection
    Pomalidomide-CO-C5-Br (Compound 6b) is a conjugated compound of the E3 ligand Pomalidomide and linker. It can be used to synthesize highly effective PROTAC molecules targeting ADC (HY-169008) .
    Pomalidomide-CO-C5-Br
  • HY-141411

    (Rac)-MRI-1867

    Cannabinoid Receptor NO Synthase Others
    (Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R)/iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis .
    (Rac)-Zevaquenabant
  • HY-163111

    Bacterial Infection
    Antibacterial agent 170 (compound 6b) is a potent antibacterial agent which inhibits the formation of P. aeruginosa PAO1 biofilm. Antibacterial agent 170 exhibits quorum sensing inhibitor effect by the las system. Antibacterial agent 170 can used in study microbial resistance .
    Antibacterial agent 170
  • HY-149803

    Sigma Receptor Neurological Disease
    S1R agonist 1 (Compound 6b) is a selective S1R agonist with Kis of 0.93 nM and 72 nM for S1R and S2R, respectively. S1R agonist 1 exhibits neuroprotection against ROS and NMDA-induced neurotoxicity .
    S1R agonist 1
  • HY-149803A

    Sigma Receptor Neurological Disease
    S1R agonist 1 (Compound 6b) hydrochloride is a selective S1R agonist with Kis of 0.93 nM and 72 nM for S1R and S2R, respectively. S1R agonist 1 hydrochloride exhibits neuroprotection against ROS and NMDA-induced neurotoxicity .
    S1R agonist 1 hydrochloride
  • HY-158181

    Adenosine Receptor Inflammation/Immunology
    A3AR agonist 5 (Compound 6b) is a A3 adenosine receptor (A3AR) activator, with EC50 and Ki values of 0.14 nM and 6.36 nM for cAMP and hA3, respectively. A3AR agonist 5 can be used in pain and inflammatory research .
    A3AR agonist 5
  • HY-156113

    RET Cancer
    RET-IN-25 (compound 6b) is a RET kinase inhibitor with anticancer activity. RET-IN-25 inhibits medullary thyroid carcinoma (MTC) with IC50s of 3.6 μM (3 days) and 3.0 μM (6 days) against TT(C634R) MTC .
    RET-IN-25
  • HY-117074

    Others Infection
    BMS-247243 is a β-lactam antibiotic against methicillin-resistant Staphylococcus aureus. This section introduces its synthesis method and biological properties. A practical synthetic method was developed to exchange iodide ions with chloride ions to form 4-thiopyridinol 6b with C-3 side chain, thereby effectively synthesizing methyl ester 12b with C-7 side chain. The reaction of 14 with methylthiolate lithium salt was catalyzed by Bu4NCl to form methyl ester 12b in high yield. Reaction with thiolate dianion gave the corresponding Michael addition byproduct, resulting in a decrease in the quality of thermodynamic product 12b. The diester 17 was synthesized by acid chlorination acylation of 16 with 12b in a two-phase system, avoiding the troublesome deprotection work such as using DCC or EDAC. During the TFA reaction to remove the protecting group 17, the bis acid 20 was unexpectedly obtained. The bis acid 19 reacted with 4-thiopyridinol 6b to form BMS-247243 in moderate yield. Alternatively, efficient coupling of diester 17 with 4-thiopyridinol 6b afforded crystalline diester 21 with little contamination from isomer 22. Double deprotection of diester 21 followed by crystallization afforded the bis-zwitterion BMS-247243 in high yield.
    BMS-247243
  • HY-160455

    Glutathione S-transferase Cancer
    GSTP1-1 inhibitor 1 (compound 6b) is an irreversible, long-acting, glutathione S-transferase inhibitor with an IC50 of 21 μM targeting GSTP1-1 . GSTP1-1 is a key tumor suppressor target, and GSTP1-1 inhibitor 1 has potential anticancer activity .
    GSTP1-1 inhibitor 1
  • HY-147814

    Bacterial Fungal Infection
    KFU-127 (Compound 6b) is a broad spectrum topical antimicrobial capable of one-shot targeting of bacterial and fungal-bacterial biofilms. KFU-127 is considerably toxic for eukaryotic cells . KFU-127 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    KFU-127
  • HY-147927

    Enteropeptidase Metabolic Disease
    Human enteropeptidase-IN-1 (compound 6b) is a highly potent, orally active and low systemic exposure enteropeptidase inhibitor. Human enteropeptidase-IN-1 boosts the increase in fecal protein output, and exhibits potent body weight loss in diet-induced obese (DIO) rat model. Human enteropeptidase-IN-1 can be used for anti-obesity research .
    Human enteropeptidase-IN-1
  • HY-161284

    MMP Cancer
    MMP-9/10-IN-1 (Compound 6b) is a potent dual MMP-9/10 Inhibotor with IC50s of 0.076 and 0.139 μM against NSCLC and A549 cells, respectively. MMP-9/10-IN-1 has anti-invasive and anti-angiogenic activities when in combination with Sorafenib (HY-10201) .
    MMP-9/10-IN-1
  • HY-130715

    PROTAC Linkers Cancer
    tert-Butyl 11-aminoundecanoate (compound 6b) is a PROTAC linker, which refers to the PEG composition. tert-Butyl 11-aminoundecanoate can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins .
    tert-Butyl 11-aminoundecanoate
  • HY-146675

    COX Inflammation/Immunology
    COX/5-LOX-IN-1 (compound 6b) is a potent and dual inhibitor of COX/5-LOX with IC50s of 1.07, 0.55, and 0.28 μM for COX-1, COX-2, and 5-LOX enzyme, respectively. COX/5-LOX-IN-1 has the potential for the research of inflammation diseases .
    COX/5-LOX-IN-1
  • HY-161442

    AMPK Inflammation/Immunology
    SIK-IN-3 (Compound 6B) is an inhibitor for salt-inducible kinase (SIK), which inhibits SKI1, SIK2 and SIK3 with IC50s of 0.1, 0.3 and 0.8 nM, respectively. SIK-IN-1 inhibits the release of TNFa with IC50 of 0.6 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 3 nM in human macrophages .
    SIK-IN-3
  • HY-143403

    PI3K Cancer
    PI3K-IN-31 (Compound 6b) is a potent PI3K inhibitor with IC50s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. PI3K-IN-31 has anticancer effects .
    PI3K-IN-31
  • HY-108418
    PI3Kδ-IN-15
    1 Publications Verification

    PI3K Cancer
    PI3Kδ-IN-15 (compound 6b) is a selective PI3Kδ inhibitor with an IC50 of 0.5 nM for p110δ. PI3Kδ-IN-15 inhibits PI3Kδ with >30-fold higher potency than PI3Kγ, PI3Kβ, and PI3Kα .
    PI3Kδ-IN-15
  • HY-N12834

    Others Inflammation/Immunology Cancer
    Ecdysoside B (compound 6b) is a pregnanoside compound isolated from the plant Ecdysanthera rosea. Ecdysoside B and its derivatives and isomers shows anticancer, immunosuppressive and anti-inflammatory activities. Ecdysoside B shows cytotoxicity to a variety of human tumor cell lines, including PANC-1 (human pancreatic cancer cells), A375 (human melanoma cells) and U87 (brain glioma U87 cells). Ecdysoside B can be used for research in the areas of cancer, immunomodulation and anti-inflammato .
    Ecdysoside B
  • HY-155073

    Microtubule/Tubulin Apoptosis Cancer
    Tubulin inhibitor 35 (compound 6b) is a dual inhibitor of topoisomerase I (IC50=~50 μM) and tubulin polymerization (IC50=5.69 μM). Tubulin inhibitor 35 inhibits migration and invasion of MGC-803 and RKO cell lines,and induces apoptosis via arresting cell cycle at G2/M phase. Tubulin inhibitor 35 exhibis potent efficacy in gastrointestinal tumor inhibiton (inhibits MGC-803 (IC50=0.09 μM) and RKO (IC50=0.2 μM) cell lines) .
    Tubulin inhibitor 35
  • HY-162772

    Isocitrate Dehydrogenase (IDH) Apoptosis Cancer
    IDH1/2-IN-1 (Compound 6b) serves as a dual inhibitor of IDH1(R132H)/IDH2(R140Q) with IC50 values of 0.22 μM and 1.6 μM, respectively. IDH1/2-IN-1 effectively inhibits tumor growth by suppressing tumor cell proliferation and enhancing host defense through the activation of antioxidant enzymes. Additionally, IDH1/2-IN-1 reduces inflammation and promotes apoptosis, demonstrating robust antitumor activity. IDH1/2-IN-1 holds potential for research in leukemia .
    IDH1/2-IN-1
  • HY-162875

    PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-27 (compound 6b) is a PROTAC that selectively targets BRD4 (rather than BRD2/BRD3) and can also inhibit the expression of KLF5 transcription factor and exert anti-cancer activity. PROTAC BRD4 Degrader-27 is composed of E3 ubiquitinase ligand Thalidomide-4-OH (HY-103596) (red part), PROTAC Linker γ-Aminobutyric acid (HY-N0067) (black part) and PROTAC target protein ligand PROTAC BRD4 ligand-3 (HY-162876) (blue part), of which the active control of the target protein ligand is Mivebresib (HY-100015), and the conjugate of E3 ubiquitin ligase ligand + Linker is Pomalidomide 4'-alkylC3-acid (HY-131875) [1] .
    PROTAC BRD4 Degrader-27

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: